1 / 3

How to Buy and Sell Martin and Harris Unlisted Shares

Start Buying and selling Martin and Harris unlisted shares by visiting Planify and get latest Martin and Harris Share Price details & Upcoming IPO information by reading our updated research report. You must know about total amount of shares, revenue growth chart, financial asset etc. before investing.

Harpreet1
Download Presentation

How to Buy and Sell Martin and Harris Unlisted Shares

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. How to Buy and SellMartin and Harris Unlisted Shares? •To Buy and Sell Martin and Harris Unlisted Shares visit Planify. Discover and get a complete analysis on Martin and Harris Laboratories Limited - Management, Business Model, Financials, Growth, Valuations, Funding Rounds, News and get latest updates on Martin and Harris Upcoming IPO. About Martin and Harris Laboratories IPO •Martin and Harris Laboratories Ltd incorporated in 1996 at Gurgaon, Haryana is a part of “Apeejay Group”, India’s oldest and largest business conglomerates. •Martin and Harris Laboratories Ltd is engaged in the manufacturing of Pharmaceutical, medicinal chemical & botanical products. Besides the core business, it has undertaken the management of its funds through investment in different avenues fetching good returns i.e., mutual funds, equity –quoted & unquoted, etc. •The company has its units located at Roorkee and UNA Himachal Pradesh •Its authorized share capital is ₹ 500,000 and its paid-up capital is ₹ 207,600. •Martin and Harris is majorly in the manufacturing (Metals & Chemicals, and products thereof) business for the last 41 years and currently, company operations are active.

  2. Martin and Harris Industry Overview Industry Statistics •In FY2020, the pharmaceutical sales grew 9% y-o-y to ₹ 10,342 Cr. India contributes the second-largest share of the pharmaceutical and biotech workforce in the world. In FY2020, the pharmaceutical sales grew 9% y-o-y to ₹ 10,342 Cr. India contributes the second largest share of the pharmaceutical and biotech workforce in the world. •Indian pharmaceutical sector supplies over 50% of the global demand for various vaccines, 40% of the generic demand for the US, and 25% of all medicines for the UK. •During December 2019, on a moving annual total (MAT) basis, industry growth was at 9.8%, with price growth at 5.3%, new product growth at 2.7%, while volume growth at 2% y-o-y. •Medicine spending in India is projected to grow 9-12% over the next five years, leading India to become one of the top 10 countries in terms of medical spending. •India's biotechnology industry comprising biopharmaceuticals, bio-services, bio-agriculture, bio-industry, and bioinformatics is expected to grow at an average growth rate of around 30% a y-o-y •to reach ₹ 7,24,800 Cr by 2025. •Indian pharmaceutical sector is expected to grow to ₹ 7,24,800 Cr, while the medical device market is expected to grow by ₹ 1,81,200 in 2025. Pharmaceuticals exports from India stood at ₹1,500,54 Cr in FY20. Pharmaceutical export includes bulk drugs, •intermediates, drug formulations, biologicals, Ayush and herbal products and surgical. Martin and Harris Strengths •Martin and Harris enjoys a High EBITDA & PAT margin compared to its listed peers. •Martin and Harris also depicts high CAGR growth in total income compared to peers over the period of 4 years. •Debt/ Equity ratio is the lowest and the Asset Turnover ratio is higher compared to peers. •The company’s EBITDA has been increasing at a CAGR of 30.9% from 2017 to 2020. •Martin and Harris Laboratories Ltd. has a higher ROCE Ratio. The company’s ROCE Ratio is 34.2% if compared to Industry Average ROCE is 21.4%. •The company’s Operating profit has been increasing at a CAGR of 30.2% from 2017 to 2020. Martin and Harris Opportunities •The COVID-19 pandemic had a moderate to high impact on the global clinical laboratory services market. •Increasing cases of COVID-19 infected patients across the globe has led to a rise in clinical chemistry services, especially in the specialized chemistry testing segment. Laboratory testing and pharma demands have increased significantly and continue to grow at a staggering rate to keep pace with suspected cases of COVID-19, thus boosting the market revenue.

  3. Get detailed information about the Martin and Harris Pre IPO shares. In this research report, you will get to know about Martin and Harris Laboratories Limited Key Ratio data. In addition, get the Complete details about the Net Profit Growth, Revenue Growth and Book Value Growth.

More Related